EGFR mutation status in brain metastases of non-small cell lung carcinoma Fanny Burel-VandenbosDamien AmbrosettiFlorence Pedeutour Topic Review 20 October 2012 Pages: 1 - 10
The role of LAT1 in 18F-DOPA uptake in malignant gliomas Ryan S. YoulandGaspar J. KitangeJann N. Sarkaria Laboratory Investigation 20 October 2012 Pages: 11 - 18
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma Kevin PetreccaMarie-Christine GuiotLuis Souhami Clinical Study 10 October 2012 Pages: 19 - 23
Post-treatment T1 shortening in primary CNS lymphoma Sasan KarimiVaios HatzoglouLisa M. Deangelis Clinical Study 17 October 2012 Pages: 25 - 31
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806) Brian M. AlexanderMeihua WangMinesh P. Mehta Clinical Study 20 October 2012 Pages: 33 - 39
Continuous daily sunitinib for recurrent glioblastoma Teri Nguyen KreislPerry SmithHoward A. Fine Clinical Study 20 October 2012 Pages: 41 - 48
Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema Tadashi OsawaMasahiko TosakaYuhei Yoshimoto Clinical Study 27 October 2012 Pages: 49 - 57
Anaplastic PXA in adults: case series with clinicopathologic and molecular features Yao SchmidtB. K. Kleinschmidt-DeMastersDenise Damek Clinical Study 25 October 2012 Pages: 59 - 69
MiR-21 expression in the tumor cell compartment holds unfavorable prognostic value in gliomas Simon Kjær HermansenRikke Hedegaard DahlrotBjarne Winther Kristensen Clinical Study 28 October 2012 Pages: 71 - 81
Epilepsy in the end-of-life phase in patients with high-grade gliomas Andrea PaceVeronica VillaniCarmine Maria Carapella Clinical Study 20 October 2012 Pages: 83 - 86
Outcome of discontinuing bevacizumab prior to malignant glioma progression Wendy J. ShermanJeffrey J. RaizerSean A. Grimm Letter to the Editor 12 October 2012 Pages: 87 - 89
Erratum to: The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas T. A. JuratliM. KirschD. Krex Erratum 27 November 2012 Pages: 95 - 95